

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and a Waiver under 18 U.S.C. §208(b)(3)

William Hiatt, M.D.

**Committee:** Oncologic Drugs Advisory Committee

**Meeting Date:** September 6, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to New Drug Applications (NDA) 020-287, Fragmin (dalteparin sodium), sponsored by Pfizer, Inc., for the proposed indication of extended treatment of symptomatic venous thromboembolism (VTE), such as proximal deep vein thromboses (DVT) and/or pulmonary embolism (PE), to reduce the recurrence of VTE in patients with cancer, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Unrelated Speaker's Bureau	2 Competitors	From \$10,001 to \$50,000 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

\_\_\_\_\_  
/s/  
Signature

\_\_\_\_\_  
8/3/06  
Date